2009

2009.04.30 Cellartis and ReproCELL Sign Agreement to Provide CardioToxicity screening service using hESC derived Cardiomyocytes

Cellartis AB, a premier provider of stem cell derived products and technologies, and ReproCELL, a Japanese biotechnology company on the forefront of stem cell platforms and screening solutions, have today signed an agreement whereby ReproCELL can commercialise its QTempo Cardiotoxicity platform using beating human embryonic stem cell (hESC) derived Cardiomyocytes from Cellartis on a fee for service basis. In this first of a kind deal, cardiotoxicity testing via the ReproCELL QTempo platform will be commercially available using live and beating hESC derived cardiomyocytes to provide more accurate models of in vivo physiology. It is expected that the QTempo platform will emerge as the next generation solution to commercial hERG screening, […]

2009.04.16 New Stem Cell Technology to Improve Drug Safety

iPS cardiomyocytes used in a novel cardiotoxicity assay Drug side effects are a major problem for the drug industry. Even very rare events, when serious enough, can warrant drug withdrawal. Unfortunately, until a drug has been used by thousands of patients, these rare events can be impossible to predict. Identifying drugs that can trigger heart attacks before they reach the clinic is a major focus of ReproCELL. Current tests, especially at early stages of drug development, tend to focus on one aspect of heart cell function – the hERG ion channel. But there are a whole range of other ion channels, as well as other possible issues, which hERG tests […]

  • «
  • 1
  • »